Real-world evidence of vosoritide treatment in children under 2 years of age with achondroplasia in Colombia: a cases series
This Colombian case series provides preliminary real-world evidence supporting the short-term safety and feasibility of vosoritide treatment in children under two years old with achondroplasia, while highlighting significant barriers to timely access and treatment continuity.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Achondroplasia is the most common form of dwarfism, a condition where the body's bones do not grow to their full length. It happens because of a specific change in a gene that acts like a brake on bone growth, telling the skeleton to stop growing too early. This leads to a shorter stature and limbs that are shorter than the torso, along with other health challenges like breathing issues or spinal compression. For decades, there was no medicine to change this growth pattern; doctors could only manage the symptoms. Then, a new treatment called vosoritide arrived. It works by gently pushing back against that genetic brake, allowing the bones to grow a bit more naturally. While this drug has been tested in older children, scientists are eager to know if starting it very early, while a child is still a baby, can make a bigger difference. This is especially important in regions where access to new medicines can be difficult, and where real-world stories about how these treatments work outside of strict laboratory settings are rare.
In Colombia, a team of doctors and researchers set out to see how this new treatment worked in the real world for the youngest patients. They followed five young girls, all diagnosed with achondroplasia, who began taking vosoritide before they turned two years old. The researchers did not run a controlled experiment with a placebo group; instead, they carefully watched what happened to these children as they received the drug in their regular clinics. They tracked how fast the girls grew, whether the medicine caused any harm, and how easy or hard it was for the families to keep getting the medication. The goal was to capture the messy, complex reality of treating a rare disease in a country where healthcare systems face unique hurdles, providing a glimpse into whether this therapy is safe and feasible for infants in Latin America.
The study found that starting this treatment in babies is possible and appears to be safe. None of the five girls suffered serious side effects from the drug. The most common issues were mild, such as feeling nauseous or having a slight increase in a specific enzyme in the blood, and these problems went away on their own. The girls continued to grow, and for those who were able to take the medicine without long breaks, their growth rates improved. Some of the children grew faster than the typical pattern seen in untreated children with achondroplasia, and their height measurements moved closer to the average for their condition. One girl, for instance, saw her growth rate reach nearly ten centimeters in a year, while another maintained a steady pace of about six centimeters. The researchers noted that the children who had the most consistent access to the drug showed the most positive changes in their growth curves.
However, the story also revealed a significant challenge that has nothing to do with the medicine itself: getting the drug. The path from a doctor's request for the medication to the family actually receiving it was long and difficult. In some cases, it took between three and six months just to get the necessary approvals and the drug in hand. Once treatment started, it was frequently interrupted because the medication ran out or delivery was delayed. Only one of the five girls received the drug without a single break during the study period. These interruptions meant that some children missed out on the full potential benefit of the therapy. The researchers observed that when treatment was stopped and started again, the children's growth slowed down, suggesting that continuous, uninterrupted use is key to seeing the best results.
Beyond just height, the study reminded everyone that children with achondroplasia face a range of other health issues that require careful attention. Even while on the new drug, the girls in the study experienced common complications of the condition, such as sleep apnea, narrowing of the spinal canal at the base of the skull, and hearing loss. This highlighted that the medicine is not a cure-all; it is a tool to help with growth, but it must be part of a larger plan that includes monitoring the spine, breathing, and ears. The children in the study generally met their developmental milestones, such as sitting up and walking, at ages expected for their condition, and their parents reported that the girls seemed more agile and mobile.
The researchers concluded that while the small number of patients and the frequent delays in getting the medicine make it hard to draw final, definitive conclusions about how well the drug works for everyone, the early signs are promising. The treatment was well-tolerated by these very young children, and it showed potential to improve growth when used consistently. The study serves as a crucial first look at how this therapy functions in a Latin American setting, proving that it can be done but also exposing the barriers that prevent families from getting the most out of it. It suggests that for the medicine to truly help, the healthcare system must be able to deliver it reliably, without long waits or gaps, ensuring that the youngest patients can benefit from the treatment during their most critical years of growth.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.